JP2000516596A5 - - Google Patents

Download PDF

Info

Publication number
JP2000516596A5
JP2000516596A5 JP1998508988A JP50898898A JP2000516596A5 JP 2000516596 A5 JP2000516596 A5 JP 2000516596A5 JP 1998508988 A JP1998508988 A JP 1998508988A JP 50898898 A JP50898898 A JP 50898898A JP 2000516596 A5 JP2000516596 A5 JP 2000516596A5
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP1998508988A
Other languages
English (en)
Japanese (ja)
Other versions
JP2000516596A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US1997/013013 external-priority patent/WO1998004247A1/en
Publication of JP2000516596A publication Critical patent/JP2000516596A/ja
Publication of JP2000516596A5 publication Critical patent/JP2000516596A5/ja
Ceased legal-status Critical Current

Links

JP10508988A 1996-07-25 1997-07-24 細胞接着インヒビター Ceased JP2000516596A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US2289096P 1996-07-25 1996-07-25
US60/022,890 1996-07-25
US3278696P 1996-12-06 1996-12-06
US60/032,786 1996-12-06
PCT/US1997/013013 WO1998004247A1 (en) 1996-07-25 1997-07-24 Cell adhesion inhibitors

Publications (2)

Publication Number Publication Date
JP2000516596A JP2000516596A (ja) 2000-12-12
JP2000516596A5 true JP2000516596A5 (https=) 2005-02-10

Family

ID=26696476

Family Applications (1)

Application Number Title Priority Date Filing Date
JP10508988A Ceased JP2000516596A (ja) 1996-07-25 1997-07-24 細胞接着インヒビター

Country Status (24)

Country Link
EP (1) EP0917462B1 (https=)
JP (1) JP2000516596A (https=)
KR (3) KR100504449B1 (https=)
CN (2) CN1230110A (https=)
AT (1) ATE339196T1 (https=)
AU (1) AU3738597A (https=)
BG (2) BG64902B1 (https=)
BR (1) BR9710570A (https=)
CA (1) CA2261848C (https=)
CZ (2) CZ298089B6 (https=)
DE (1) DE69736669T2 (https=)
EA (1) EA005526B1 (https=)
EE (1) EE04604B1 (https=)
ES (1) ES2271971T3 (https=)
IL (1) IL128221A (https=)
IS (1) IS4955A (https=)
NO (1) NO990338L (https=)
NZ (1) NZ333904A (https=)
PL (2) PL190866B1 (https=)
PT (2) PT917462E (https=)
SG (2) SG124234A1 (https=)
SK (1) SK8199A3 (https=)
TR (1) TR199900781T2 (https=)
WO (2) WO1998004247A1 (https=)

Families Citing this family (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002501518A (ja) * 1997-05-30 2002-01-15 セルテック セラピューティックス リミテッド 抗炎症性チロシン誘導体
US6362341B1 (en) 1997-07-31 2002-03-26 Athena Neurosciences, Inc. Benzyl compounds which inhibit leukocyte adhesion mediated by VLA-4
US6559127B1 (en) 1997-07-31 2003-05-06 Athena Neurosciences, Inc. Compounds which inhibit leukocyte adhesion mediated by VLA-4
US6939855B2 (en) 1997-07-31 2005-09-06 Elan Pharmaceuticals, Inc. Anti-inflammatory compositions and method
US6423688B1 (en) 1997-07-31 2002-07-23 Athena Neurosciences, Inc. Dipeptide and related compounds which inhibit leukocyte adhesion mediated by VLA-4
US6492421B1 (en) 1997-07-31 2002-12-10 Athena Neurosciences, Inc. Substituted phenylalanine type compounds which inhibit leukocyte adhesion mediated by VLA-4
US6489300B1 (en) 1997-07-31 2002-12-03 Eugene D. Thorsett Carbamyloxy compounds which inhibit leukocyte adhesion mediated by VLA-4
US6583139B1 (en) 1997-07-31 2003-06-24 Eugene D. Thorsett Compounds which inhibit leukocyte adhesion mediated by VLA-4
US6291453B1 (en) 1997-07-31 2001-09-18 Athena Neurosciences, Inc. 4-amino-phenylalanine type compounds which inhibit leukocyte adhesion mediated by VLA-4
US7030114B1 (en) 1997-07-31 2006-04-18 Elan Pharmaceuticals, Inc. Compounds which inhibit leukocyte adhesion mediated by VLA-4
DE19741235A1 (de) 1997-09-18 1999-03-25 Hoechst Marion Roussel De Gmbh Neue Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
DE19741873A1 (de) * 1997-09-23 1999-03-25 Hoechst Marion Roussel De Gmbh Neue 5-Ring-Heterocyclen, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
BR9813331A (pt) 1997-10-31 2000-08-22 Aventis Pharma Ltd Composto, uso do mesmo, composição farmacêutica, processo para o tratamento de um paciente humano ou animal não humano que sofra ou esteja sujeito a condições que possam ser melhoradas pela administração de um inibidor da adesão celular mediada pela a4b1, e, resina
GB9723789D0 (en) 1997-11-12 1998-01-07 Zeneca Ltd Chemical compounds
DE19751251A1 (de) 1997-11-19 1999-05-20 Hoechst Marion Roussel De Gmbh Substituierte Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmezeutische Präparate
US6645939B1 (en) 1997-11-24 2003-11-11 Merck & Co., Inc. Substituted β-alanine derivatives as cell adhesion inhibitors
AU751950B2 (en) * 1997-11-24 2002-09-05 Merck & Co., Inc. Substituted beta-alanine derivatives as cell adhesion inhibitors
US6407065B1 (en) 1998-01-23 2002-06-18 Novartis Ag VLA-4 antagonists
US6329372B1 (en) 1998-01-27 2001-12-11 Celltech Therapeutics Limited Phenylalanine derivatives
GB9805655D0 (en) 1998-03-16 1998-05-13 Celltech Therapeutics Ltd Chemical compounds
US6521626B1 (en) 1998-03-24 2003-02-18 Celltech R&D Limited Thiocarboxamide derivatives
DE69939165D1 (de) 1998-04-16 2008-09-04 Encysive Pharmaceuticals Inc N,n-disubstituierte amide welche die bindung von integrinen an ihre rezeptoren hemmen
DE19821483A1 (de) 1998-05-14 1999-11-18 Hoechst Marion Roussel De Gmbh Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
GB9811159D0 (en) 1998-05-22 1998-07-22 Celltech Therapeutics Ltd Chemical compounds
HUP0102255A3 (en) * 1998-05-28 2001-12-28 Biogen Idec Ma Inc Cambridge Vla-4 inhibitor omepupa-v, pharmaceutical compositions comprising thereof and their use
GB9811969D0 (en) * 1998-06-03 1998-07-29 Celltech Therapeutics Ltd Chemical compounds
GB9814414D0 (en) 1998-07-03 1998-09-02 Celltech Therapeutics Ltd Chemical compounds
AU1915399A (en) * 1998-07-10 2000-02-01 Cytel Corporation Cs-1 peptidomimetics, compositions and methods of using the same
US6352977B1 (en) 1998-07-13 2002-03-05 Aventis Pharma Limited Substituted β-alanines
GB9916374D0 (en) 1998-07-23 1999-09-15 Zeneca Ltd Chemical compounds
GB9821061D0 (en) 1998-09-28 1998-11-18 Celltech Therapeutics Ltd Chemical compounds
GB9821222D0 (en) 1998-09-30 1998-11-25 Celltech Therapeutics Ltd Chemical compounds
GB9825652D0 (en) 1998-11-23 1999-01-13 Celltech Therapeutics Ltd Chemical compounds
GB9826174D0 (en) 1998-11-30 1999-01-20 Celltech Therapeutics Ltd Chemical compounds
US6407066B1 (en) 1999-01-26 2002-06-18 Elan Pharmaceuticals, Inc. Pyroglutamic acid derivatives and related compounds which inhibit leukocyte adhesion mediated by VLA-4
GB9909409D0 (en) * 1999-04-24 1999-06-23 Zeneca Ltd Chemical compounds
JP4707240B2 (ja) * 1999-05-05 2011-06-22 アベンティス・フアーマ・リミテッド 細胞接着調節剤としての尿素
US6723711B2 (en) 1999-05-07 2004-04-20 Texas Biotechnology Corporation Propanoic acid derivatives that inhibit the binding of integrins to their receptors
US6972296B2 (en) 1999-05-07 2005-12-06 Encysive Pharmaceuticals Inc. Carboxylic acid derivatives that inhibit the binding of integrins to their receptors
BR0010349B1 (pt) * 1999-05-07 2011-10-04 derivados de ácido propanóico que inibem a ligação de integrinas aos seus receptores.
JP3620577B2 (ja) * 1999-05-14 2005-02-16 栗田工業株式会社 超純水製造システムの洗浄方法
DE19922462A1 (de) 1999-05-17 2000-11-23 Aventis Pharma Gmbh Spiro-imidazolidinderivate, ihre Herstellung ihre Verwendung und sie enthaltende pharmazeutische Präparate
US6518283B1 (en) 1999-05-28 2003-02-11 Celltech R&D Limited Squaric acid derivatives
US6756378B2 (en) 1999-06-30 2004-06-29 Pharmacopeia Drug Discovery, Inc. VLA-4 inhibitor compounds
AU5826100A (en) 1999-07-13 2001-01-30 F. Hoffmann-La Roche Ag Benzazepinones and quinazolines
GEP20053477B (en) 1999-08-13 2005-03-25 Biogen Inc Cell Adhesion Inhibitors and Pharmaceutical Compositions Containing Them
ES2263485T3 (es) * 1999-09-14 2006-12-16 Biogen Idec Ma Inc. Terapia para insuficiencia renal cronica utilizando uno o mas angtagonistas de integrinas.
EP1700606A1 (en) * 1999-09-14 2006-09-13 Biogen Idec MA, Inc. Therapies for chronic renal failure using one or more integrin antagonists
US6534513B1 (en) 1999-09-29 2003-03-18 Celltech R&D Limited Phenylalkanoic acid derivatives
CA2388686A1 (en) * 1999-12-07 2001-06-14 Sompong Wattanasin Vla-4 integrin antagonists
US6455539B2 (en) 1999-12-23 2002-09-24 Celltech R&D Limited Squaric acid derivates
EP1244656A1 (en) * 1999-12-28 2002-10-02 Pfizer Products Inc. Non-peptidyl inhibitors of vla-4 dependent cell binding useful in treating inflammatory, autoimmune, and respiratory diseases
GB0001348D0 (en) * 2000-01-21 2000-03-08 Astrazeneca Uk Ltd Chemical compounds
DE10006453A1 (de) * 2000-02-14 2001-08-16 Bayer Ag Piperidylcarbonsäuren als Integrinantagonisten
AU2001248553A1 (en) 2000-04-17 2001-10-30 Celltech R And D Limited Enamine derivatives as cell adhesion molecules
GB0011817D0 (en) * 2000-05-16 2000-07-05 Pharmacia & Upjohn Spa Antagonists of integrin receptors
US6545013B2 (en) 2000-05-30 2003-04-08 Celltech R&D Limited 2,7-naphthyridine derivatives
US6403608B1 (en) 2000-05-30 2002-06-11 Celltech R&D, Ltd. 3-Substituted isoquinolin-1-yl derivatives
US7065453B1 (en) 2000-06-15 2006-06-20 Accelrys Software, Inc. Molecular docking technique for screening of combinatorial libraries
WO2001098268A2 (en) 2000-06-21 2001-12-27 Bristol-Myers Squibb Pharma Company Piperidine amides as modulators of chemokine receptor activity
WO2002004426A1 (en) 2000-07-07 2002-01-17 Celltech R & D Limited Squaric acid derivatives containing a bicyclic heteroaromatic ring as integrin antagonists
EP1305291A1 (en) 2000-08-02 2003-05-02 Celltech R&D Limited 3-substituted isoquinolin-1-yl derivatives
GB2369357A (en) * 2000-10-09 2002-05-29 Bayer Ag Aliphatic, cyclic amino carboxylic acids as integrin antagonists
AU2002248142B2 (en) * 2000-11-28 2007-11-01 Genentech, Inc. LFA-1 antagonist compounds
US7157487B2 (en) 2000-12-28 2007-01-02 Daiichi Pharmaceutical Co., Ltd. Vla-4 inhibitors
ES2200617B1 (es) 2001-01-19 2005-05-01 Almirall Prodesfarma, S.A. Derivados de urea como antagonistas de integrinas alfa 4.
PL364625A1 (en) 2001-02-23 2004-12-13 Merck & Co, Inc. N-substituted nonaryl-heterocyclic nmda/nr2b antagonists
DE10111877A1 (de) 2001-03-10 2002-09-12 Aventis Pharma Gmbh Neue Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
WO2002080928A1 (en) 2001-04-03 2002-10-17 Merck & Co., Inc. N-substituted nonaryl-heterocyclo amidyl nmda/nr2b antagonists
US7056917B2 (en) 2001-04-26 2006-06-06 Daiichi Pharmaceutical Co., Ltd. Drug efflux pump inhibitor
GB2377933A (en) * 2001-07-06 2003-01-29 Bayer Ag Succinic acid derivatives useful as integrin antagonists
DE10137595A1 (de) 2001-08-01 2003-02-13 Aventis Pharma Gmbh Neue Imidazolidinderivate, ihre Herstellung und ihre Verwendung
EP1650205B1 (en) 2003-07-24 2012-04-25 Daiichi Sankyo Company, Limited Cyclohexanecarboxylic acid compound
WO2005066124A1 (ja) * 2003-12-26 2005-07-21 Daiichi Pharmaceutical Co., Ltd. ピロリジン誘導体の製造法
US7196112B2 (en) 2004-07-16 2007-03-27 Biogen Idec Ma Inc. Cell adhesion inhibitors
GB0517292D0 (en) * 2005-08-24 2005-10-05 Univ Dundee Cell migration modulating compounds
EP2124996A4 (en) 2007-02-20 2010-03-24 Merrimack Pharmaceuticals Inc METHOD FOR TREATING MULTIPLE SCLEROSIS BY ADMINISTERING AN ALPHA FETOPROTEIN COMBINED WITH AN INTEGRINANT AGONIST
JP2010520875A (ja) 2007-03-09 2010-06-17 レノビス, インコーポレイテッド P2x7調節因子としてのビシクロヘテロアリール化合物およびその使用
CA2721093A1 (en) 2008-04-11 2009-10-15 Merrimack Pharmaceuticals, Inc. Human serum albumin linkers and conjugates thereof
US8563690B2 (en) 2008-11-03 2013-10-22 The Board Of Trustees Of The University Of Illinois Modulation of platelet aggregation
SMT202000306T1 (it) 2010-04-16 2020-07-08 Biogen Ma Inc Anticorpi anti-vla-4
US20140094512A1 (en) 2012-10-02 2014-04-03 Nikolas Gunkel Method of modulating the degree of adipose tissue deposited intramuscularly
US10875875B2 (en) 2017-04-26 2020-12-29 Aviara Pharmaceuticals, Inc. Propionic acid derivatives and methods of use thereof
US12037398B2 (en) 2018-06-04 2024-07-16 Biogen Ma Inc. Anti-VLA-4 antibodies having reduced effector function
KR102659859B1 (ko) 2018-10-30 2024-04-25 길리애드 사이언시즈, 인코포레이티드 알파4β7 인테그린의 억제를 위한 화합물
CN112969700B (zh) 2018-10-30 2024-08-20 吉利德科学公司 作为α4β7整合素抑制剂的咪唑并吡啶衍生物
AU2019373242B2 (en) 2018-10-30 2023-07-13 Gilead Sciences, Inc. Compounds for inhibition of alpha 4 beta 7 integrin
EP4541422A3 (en) 2018-10-30 2025-06-25 Gilead Sciences, Inc. Quinoline derivatives as alpha4beta7 integrin inhibitors
KR102908219B1 (ko) 2019-08-14 2026-01-08 길리애드 사이언시즈, 인코포레이티드 알파 4 베타 7 인테그린의 저해용 화합물

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5256812A (en) * 1989-01-31 1993-10-26 Hoffmann-La Roche Inc. Carboxamides and sulfonamides
US5084466A (en) * 1989-01-31 1992-01-28 Hoffmann-La Roche Inc. Novel carboxamide pyridine compounds which have useful pharmaceutical utility
CA2072363A1 (en) * 1989-12-29 1991-06-30 Graham J. Moore Methods for modelling tertiary structures of biologically active ligands including agonists and antagonists thereto and novel synthetic antagonists based on angiotensin
US5260277A (en) * 1990-09-10 1993-11-09 Tanabe Seiyaku Co., Ltd. Guanidinyl and related cell adhesion modulation compounds
WO1992008464A1 (en) * 1990-11-15 1992-05-29 Tanabe Seiyaku Co. Ltd. Substituted urea and related cell adhesion modulation compounds
AU666318B2 (en) * 1991-06-28 1996-02-08 Smithkline Beecham Corporation Bicyclic fibrinogen antagonists
US5250679A (en) * 1991-10-18 1993-10-05 Genentech, Inc. Nonpeptidyl platelet aggregation inhibitors having specificity for the GPIIb III.sub. receptor
WO1993008823A1 (en) * 1991-11-06 1993-05-13 Tanabe Seiyaku Co., Ltd. Guanidinyl and related cell adhesion modulation compounds
US5272162A (en) * 1992-07-02 1993-12-21 G. D. Searle & Co. Platelet aggregation inhibitors
US5358956A (en) * 1992-10-14 1994-10-25 Merck & Co., Inc. Fibrinogen receptor antagonists
US5340798A (en) * 1992-10-14 1994-08-23 Merck & Co., Inc. Fibrinogen receptor antagonists
DE4302485A1 (de) * 1993-01-29 1994-08-04 Merck Patent Gmbh Piperazinderivate
WO1994018981A1 (en) * 1993-02-22 1994-09-01 Merck & Co., Inc. Fibrinogen receptor antagonists
AU6395094A (en) * 1993-03-15 1994-10-11 G.D. Searle & Co. Urea derivatives useful as platelet aggregation inhibitors
WO1994022444A1 (en) * 1993-03-29 1994-10-13 Smithkline Beecham Corporation Tricyclic compounds for inhibiting platelet aggregation
CA2159450C (en) * 1993-03-31 2002-01-08 Norman Anthony Abood 1-amidinophenyl-pyrrolidones piperidinones azetinones as platelet aggregation inhibitors
US5441952A (en) * 1993-04-05 1995-08-15 Merck & Co., Inc. Fibrinogen receptor antagonists
IL110172A (en) * 1993-07-22 2001-10-31 Lilly Co Eli Bicyclic compounds and pharmaceutical compositions containing them
DE4332384A1 (de) * 1993-09-23 1995-03-30 Merck Patent Gmbh Adhäsionsrezeptor-Antagonisten III
DE4341665A1 (de) * 1993-12-07 1995-06-08 Basf Ag Bicyclen-Derivate, ihre Herstellung und Verwendung
DE4405378A1 (de) * 1994-02-19 1995-08-24 Merck Patent Gmbh Adhäsionsrezeptor-Antagonisten
US5525617A (en) * 1994-08-24 1996-06-11 Merck & Co., Inc. Fibrinogen receptor antagonists

Similar Documents

Publication Publication Date Title
JP2001505705A5 (https=)
JP2001519648A5 (https=)
JP2000517231A5 (https=)
JP2000507119A5 (https=)
JP2001500276A5 (https=)
JP2000516596A5 (https=)
JP2001501471A5 (https=)
JP2000515062A5 (https=)
JP2001500477A5 (https=)
JP2001512478A5 (https=)
JP2001505855A5 (https=)
JP2000515801A5 (https=)
JP2001505497A5 (https=)
JP2001504996A5 (https=)
JP2001500092A5 (https=)
JP2000502931A5 (https=)
JP2000516592A5 (https=)
JP2001503448A5 (https=)
JP2000505916A5 (https=)
JP2001500723A5 (https=)
JP2001502315A5 (https=)
JP2001501929A5 (https=)
JP2000516610A5 (https=)
JP2000515187A5 (https=)
JP2001504189A5 (https=)